CHSJ

Curr Health Sci J, vol. 48, no. 2, 2022

VEGF Immunoexpression in Endometrioid Endometrial Carcinomas

[Original Paper]

I. DROCAS(1), S. CRAITOIU(2), A.E. STEPAN(3), C.E. SIMIONESCU(3), D. MARINESCU(4)


(1)PhD Student, Department of Histology, University of Medicine and Pharmacy of Craiova, Romania;
(2)Department of Histology, University of Medicine and Pharmacy of Craiova, Romania;
(3)Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania;
(4)Department of General Surgery, University of Medicine and Pharmacy of Craiova


Abstract:

Vascular endothelial growth factor (VEGF) is the most important stimulator of endometrial tumor angiogenesis, a mechanism that may be a therapeutic target in the context of an incidence and persistent mortality of endometrial endometrial carcinomas (EEC). In this study, VEGF immunoexpression was analyzed for 50 cases of EEC in relation to the histopathological parameters of tumor aggressiveness. High VEGF scores have been associated with the high grade and advanced stage of EEC, but unrelated to the depth of myometrial invasion, the pattern of tumor invasion, or vascular invasion. VEGF may be useful for assessing EEC aggression, but also for tumor angiogenic potential, which recommends it as a possible mark for specific antitumor therapy.


Keywords: Endometrioid endometrial carcinomas, VEGF, tumor grade, tumor stage.



Corresponding: Cristiana Eugenia Simionescu, Department of Pathology, University of Medicine and Pharmacy of Craiova, 66 1 May Avenue, 200628 Craiova, Romania e-mail: csimionescu2004@yahoo.com


DOI 10.12865/CHSJ.48.02.03 - Download PDF
current issue cover Download cover
Download contents

Journal archive